<DOC>
	<DOCNO>NCT00140621</DOCNO>
	<brief_summary>This multi-center , open label , phase IV study conduct evaluate efficacy safety agalsidase beta ( Fabrazyme [ recombinant form ] ) administer intravenous drip infusion participant cardiac Fabry disease . Participants participate 4 week less baseline period 156 week treatment period .</brief_summary>
	<brief_title>A Safety Efficacy Study Fabrazyme® Replacement Therapy Patients With Cardiac Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Participants definitively diagnose cardiac Fabry disease ( fulfill follow criterion ) In case male participant , document plasma leukocyte alphagalactosidase A ( αGAL ) activity 20 percent ( % ) normal value ( except heterozygous female participant ) Left ventricular hypertrophy note . Accumulation globotriaosylceramide ( GL3 ) myocardium genetic deficiency associate αGAL confirm Or case heterozygous female participant , family ( father son ) diagnose Fabry disease . ( Father son relate birth . ) Without symptom sign Fabry , acroparesthesia , angiokeratomas , abnormal sweating , pain distal extremity , chronic abdominal pain/diarrhea corneal opacity observe , except proteinuria sign . Participants interventricular posterior wall thickness least 13 millimeter ( mm ) echocardiography within 3 month sign date inform consent Participants cardiac function rat Class I II accord New York Heart Association ( NYHA ) classification give informed consent . Participants classification : inpatient outpatients Participants give write informed consent studyrelated baseline test . Participants severe hypertension ( example , blood pressure equal 180 millimeter mercury [ mmHg ] and/or blood pressure equal 110 mmHg spite adequate medication ) Participants whose serum creatinine level high upper normal limit within 3 month ( 12 week ) prior give inform consent . Participants undergone kidney transplantation currently dialysis . Participants serious hepatic disorder . Participants abnormal hepatic function test value within 3 month ( 12 week ) prior give inform consent ( either alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] level exceed value five time high upper normal limit ) . Permanent pacemaker defibrillator implant participant Pregnant lactate woman Participants take drug 6 month ( 26 week ) give informed consent . Participants participate clinical study employ investigational product within 3 month prior give inform consent . Enzyme replacement therapy history , except agalsidase beta Participants unwilling comply requirement protocol . Others judge investigator subinvestigator ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>cardiac fabry disease</keyword>
</DOC>